Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Ovid Therapeutics Inc (NASDAQ: OVID) was $1.64 for the day, up 19.71% from the previous closing price of $1.37. In other words, the price has increased by $19.71 from its previous closing price. On the day, 2.96 million shares were traded. OVID stock price reached its highest trading level at $1.675 during the session, while it also had its lowest trading level at $1.37.
Ratios:
Our analysis of OVID’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.72 and its Current Ratio is at 4.72. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.23.
On April 30, 2024, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $9.B. Riley Securities initiated its Buy rating on April 30, 2024, with a $9 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 26 ’25 when ALEXANDER MARGARET A. sold 5,279 shares for $0.56 per share. The transaction valued at 2,956 led to the insider holds 73,406 shares of the business.
Rona Jeffrey A sold 3,902 shares of OVID for $2,185 on Feb 26 ’25. The CBFO now owns 67,973 shares after completing the transaction at $0.56 per share. On Jan 27 ’25, another insider, ALEXANDER MARGARET A., who serves as the President and COO of the company, bought 6,810 shares for $0.73 each. As a result, the insider paid 4,971 and bolstered with 34,935 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OVID now has a Market Capitalization of 116619600 and an Enterprise Value of 92371600. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.54 while its Price-to-Book (P/B) ratio in mrq is 2.09. Its current Enterprise Value per Revenue stands at 13.888 whereas that against EBITDA is -2.242.
Stock Price History:
The Beta on a monthly basis for OVID is 0.31, which has changed by 0.4260869 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, OVID has reached a high of $1.82, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is 59.94%, while the 200-Day Moving Average is calculated to be 160.33%.
Shares Statistics:
OVID traded an average of 2.06M shares per day over the past three months and 2879930 shares per day over the past ten days. A total of 71.11M shares are outstanding, with a floating share count of 59.52M. Insiders hold about 16.29% of the company’s shares, while institutions hold 34.63% stake in the company. Shares short for OVID as of 1757894400 were 488729 with a Short Ratio of 0.24, compared to 1755216000 on 1511017. Therefore, it implies a Short% of Shares Outstanding of 488729 and a Short% of Float of 0.8200000000000001.
Earnings Estimates
Current recommendations for the stock of the company come from 4.0 analysts. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.45 and -$0.51 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is -$0.55, with 4.0 analysts recommending between -$0.4 and -$0.72.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for OVID’s current fiscal year. The highest revenue estimate was $7.39M, while the lowest revenue estimate was $6.4M, resulting in an average revenue estimate of $6.7M. In the same quarter a year ago, actual revenue was $566k
